On December 30, 2024, Geno Germano, Director at Precision BioSciences Inc (DTIL, Financial), purchased 3,605 shares of the company. Following this transaction, the insider now owns a total of 7,807 shares. The transaction details can be found in the SEC Filing.
Precision BioSciences Inc is a biotechnology company focused on developing genome editing technologies to treat genetic disorders and improve food production. The company aims to leverage its proprietary ARCUS genome editing platform to create innovative solutions in the fields of human health and agriculture.
The insider transaction history for Precision BioSciences Inc indicates a total of five insider buys and thirteen insider sells over the past year. This recent purchase by Geno Germano is part of the buying trend observed among insiders.
On the day of the purchase, shares of Precision BioSciences Inc were trading at $4.49, giving the stock a market cap of $29.227 million. The company's price-earnings ratio stands at 63.50, which is higher than the industry median of 25.785 but lower than the company's historical median price-earnings ratio.
With a current price of $4.49 and a GF Value of $14.38, Precision BioSciences Inc has a price-to-GF-Value ratio of 0.31. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
